Somatic mutations in MAP3K5 attenuate its proapoptotic function in melanoma through increased binding to thioredoxin

Todd D. Prickett, Brad Zerlanko, Jared J. Gartner, Stephen C J Parker, Ken Dutton-Regester, Jimmy C. Lin, Jamie K. Teer, Xiaomu Wei, Jiji Jiang, Guo Chen, Michael A. Davies, Jeffrey E. Gershenwald, William Robinson, Steven Robinson, Nicholas K. Hayward, Steven A. Rosenberg, Elliott H. Margulies, Yardena Samuels

Research output: Contribution to journalArticle

Abstract

Patients with advanced metastatic melanoma have poor prognosis and the genetics underlying its pathogenesis are poorly understood. High-throughput sequencing has allowed comprehensive discovery of somatic mutations in cancer samples. Here, on analysis of our whole-genome and whole-exome sequencing data of 29 melanoma samples, we identified several genes that harbor recurrent nonsynonymous mutations. These included MAP3K5 (mitogen-activated protein kinase kinase kinase-5), which in a prevalence screen of 288 melanomas was found to harbor a R256C substitution in 5 cases. All MAP3K5-mutated samples were wild type for BRAF, suggesting a mutual exclusivity for these mutations. Functional analysis of the MAP3K5 R256C mutation revealed attenuation of MKK4 (mitogen-activated protein kinase kinase 4) activation through increased binding of the inhibitory protein thioredoxin (TXN/TRX-1/Trx), resulting in increased proliferation and anchorage-independent growth of melanoma cells. This mutation represents a potential target for the design of new therapies to treat melanoma.

Original languageEnglish (US)
Pages (from-to)452-460
Number of pages9
JournalJournal of Investigative Dermatology
Volume134
Issue number2
DOIs
StatePublished - Feb 2014
Externally publishedYes

Fingerprint

Thioredoxins
Ports and harbors
Melanoma
Genes
MAP Kinase Kinase 4
MAP Kinase Kinase Kinases
Functional analysis
Mutation
Substitution reactions
Chemical activation
Throughput
Exome
Proteins
Carrier Proteins
Genome
Growth
Neoplasms
Genetics

ASJC Scopus subject areas

  • Dermatology
  • Biochemistry
  • Cell Biology
  • Molecular Biology

Cite this

Prickett, T. D., Zerlanko, B., Gartner, J. J., Parker, S. C. J., Dutton-Regester, K., Lin, J. C., ... Samuels, Y. (2014). Somatic mutations in MAP3K5 attenuate its proapoptotic function in melanoma through increased binding to thioredoxin. Journal of Investigative Dermatology, 134(2), 452-460. https://doi.org/10.1038/jid.2013.365

Somatic mutations in MAP3K5 attenuate its proapoptotic function in melanoma through increased binding to thioredoxin. / Prickett, Todd D.; Zerlanko, Brad; Gartner, Jared J.; Parker, Stephen C J; Dutton-Regester, Ken; Lin, Jimmy C.; Teer, Jamie K.; Wei, Xiaomu; Jiang, Jiji; Chen, Guo; Davies, Michael A.; Gershenwald, Jeffrey E.; Robinson, William; Robinson, Steven; Hayward, Nicholas K.; Rosenberg, Steven A.; Margulies, Elliott H.; Samuels, Yardena.

In: Journal of Investigative Dermatology, Vol. 134, No. 2, 02.2014, p. 452-460.

Research output: Contribution to journalArticle

Prickett, TD, Zerlanko, B, Gartner, JJ, Parker, SCJ, Dutton-Regester, K, Lin, JC, Teer, JK, Wei, X, Jiang, J, Chen, G, Davies, MA, Gershenwald, JE, Robinson, W, Robinson, S, Hayward, NK, Rosenberg, SA, Margulies, EH & Samuels, Y 2014, 'Somatic mutations in MAP3K5 attenuate its proapoptotic function in melanoma through increased binding to thioredoxin', Journal of Investigative Dermatology, vol. 134, no. 2, pp. 452-460. https://doi.org/10.1038/jid.2013.365
Prickett, Todd D. ; Zerlanko, Brad ; Gartner, Jared J. ; Parker, Stephen C J ; Dutton-Regester, Ken ; Lin, Jimmy C. ; Teer, Jamie K. ; Wei, Xiaomu ; Jiang, Jiji ; Chen, Guo ; Davies, Michael A. ; Gershenwald, Jeffrey E. ; Robinson, William ; Robinson, Steven ; Hayward, Nicholas K. ; Rosenberg, Steven A. ; Margulies, Elliott H. ; Samuels, Yardena. / Somatic mutations in MAP3K5 attenuate its proapoptotic function in melanoma through increased binding to thioredoxin. In: Journal of Investigative Dermatology. 2014 ; Vol. 134, No. 2. pp. 452-460.
@article{43f2cb76bb0a4fea87921482283126a1,
title = "Somatic mutations in MAP3K5 attenuate its proapoptotic function in melanoma through increased binding to thioredoxin",
abstract = "Patients with advanced metastatic melanoma have poor prognosis and the genetics underlying its pathogenesis are poorly understood. High-throughput sequencing has allowed comprehensive discovery of somatic mutations in cancer samples. Here, on analysis of our whole-genome and whole-exome sequencing data of 29 melanoma samples, we identified several genes that harbor recurrent nonsynonymous mutations. These included MAP3K5 (mitogen-activated protein kinase kinase kinase-5), which in a prevalence screen of 288 melanomas was found to harbor a R256C substitution in 5 cases. All MAP3K5-mutated samples were wild type for BRAF, suggesting a mutual exclusivity for these mutations. Functional analysis of the MAP3K5 R256C mutation revealed attenuation of MKK4 (mitogen-activated protein kinase kinase 4) activation through increased binding of the inhibitory protein thioredoxin (TXN/TRX-1/Trx), resulting in increased proliferation and anchorage-independent growth of melanoma cells. This mutation represents a potential target for the design of new therapies to treat melanoma.",
author = "Prickett, {Todd D.} and Brad Zerlanko and Gartner, {Jared J.} and Parker, {Stephen C J} and Ken Dutton-Regester and Lin, {Jimmy C.} and Teer, {Jamie K.} and Xiaomu Wei and Jiji Jiang and Guo Chen and Davies, {Michael A.} and Gershenwald, {Jeffrey E.} and William Robinson and Steven Robinson and Hayward, {Nicholas K.} and Rosenberg, {Steven A.} and Margulies, {Elliott H.} and Yardena Samuels",
year = "2014",
month = "2",
doi = "10.1038/jid.2013.365",
language = "English (US)",
volume = "134",
pages = "452--460",
journal = "Journal of Investigative Dermatology",
issn = "0022-202X",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Somatic mutations in MAP3K5 attenuate its proapoptotic function in melanoma through increased binding to thioredoxin

AU - Prickett, Todd D.

AU - Zerlanko, Brad

AU - Gartner, Jared J.

AU - Parker, Stephen C J

AU - Dutton-Regester, Ken

AU - Lin, Jimmy C.

AU - Teer, Jamie K.

AU - Wei, Xiaomu

AU - Jiang, Jiji

AU - Chen, Guo

AU - Davies, Michael A.

AU - Gershenwald, Jeffrey E.

AU - Robinson, William

AU - Robinson, Steven

AU - Hayward, Nicholas K.

AU - Rosenberg, Steven A.

AU - Margulies, Elliott H.

AU - Samuels, Yardena

PY - 2014/2

Y1 - 2014/2

N2 - Patients with advanced metastatic melanoma have poor prognosis and the genetics underlying its pathogenesis are poorly understood. High-throughput sequencing has allowed comprehensive discovery of somatic mutations in cancer samples. Here, on analysis of our whole-genome and whole-exome sequencing data of 29 melanoma samples, we identified several genes that harbor recurrent nonsynonymous mutations. These included MAP3K5 (mitogen-activated protein kinase kinase kinase-5), which in a prevalence screen of 288 melanomas was found to harbor a R256C substitution in 5 cases. All MAP3K5-mutated samples were wild type for BRAF, suggesting a mutual exclusivity for these mutations. Functional analysis of the MAP3K5 R256C mutation revealed attenuation of MKK4 (mitogen-activated protein kinase kinase 4) activation through increased binding of the inhibitory protein thioredoxin (TXN/TRX-1/Trx), resulting in increased proliferation and anchorage-independent growth of melanoma cells. This mutation represents a potential target for the design of new therapies to treat melanoma.

AB - Patients with advanced metastatic melanoma have poor prognosis and the genetics underlying its pathogenesis are poorly understood. High-throughput sequencing has allowed comprehensive discovery of somatic mutations in cancer samples. Here, on analysis of our whole-genome and whole-exome sequencing data of 29 melanoma samples, we identified several genes that harbor recurrent nonsynonymous mutations. These included MAP3K5 (mitogen-activated protein kinase kinase kinase-5), which in a prevalence screen of 288 melanomas was found to harbor a R256C substitution in 5 cases. All MAP3K5-mutated samples were wild type for BRAF, suggesting a mutual exclusivity for these mutations. Functional analysis of the MAP3K5 R256C mutation revealed attenuation of MKK4 (mitogen-activated protein kinase kinase 4) activation through increased binding of the inhibitory protein thioredoxin (TXN/TRX-1/Trx), resulting in increased proliferation and anchorage-independent growth of melanoma cells. This mutation represents a potential target for the design of new therapies to treat melanoma.

UR - http://www.scopus.com/inward/record.url?scp=84892810694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892810694&partnerID=8YFLogxK

U2 - 10.1038/jid.2013.365

DO - 10.1038/jid.2013.365

M3 - Article

C2 - 24008424

AN - SCOPUS:84892810694

VL - 134

SP - 452

EP - 460

JO - Journal of Investigative Dermatology

JF - Journal of Investigative Dermatology

SN - 0022-202X

IS - 2

ER -